Anti-c5a antibodies and methods for using the antibodies

A technology of antibodies and antigens, applied in chemical instruments and methods, antibodies, antibody medical components, etc., can solve problems such as inability to form C5 converting enzymes

Inactive Publication Date: 2013-07-10
ALEXION PHARMA INC
View PDF155 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although still opsonic, iC3b fail

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-c5a antibodies and methods for using the antibodies
  • Anti-c5a antibodies and methods for using the antibodies
  • Anti-c5a antibodies and methods for using the antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0400] Example 1. Immunization method

[0401] The anti-C5a antibody of the present invention is a humanized form of murine antibody prepared under the following immunization protocol. Immunizations producing antibodies against human desarginated C5a were performed on 4 mice, including 2 mice of the DBA / 2J strain and 2 mice of the A / J strain. These lines were chosen because they carry alleles Hc 0 , which would render them deficient in endogenous C5. All immunizations were repeated at 14 day intervals for a total of 3 immunizations. Approximately 14 days after the last immunization and 5–7 days before harvest, all animals received a subcutaneous booster immunization of approximately 50 μg of purified C5a (in 200 μL of adjuvant emulsion). Using an ELISA assay, titration of sera from immunized mice confirmed that the mice exhibited a strong antibody response against the human desarginated C5a immunogen.

Embodiment 2

[0402] Example 2. Determination of the specificity of mouse antibodies to human C5a

[0403]A panel of 5 mouse anti-human C5a Fabs, representative of neoepitope-selective Fabs, were converted into full-length mouse IgG2a antibodies, named: 5an048ME, 5an101ME, 5an178ME, 5an179ME and 5an180ME. The specificity of these antibodies was evaluated using the Biolayer Interferometry method on Octet (ForteBio Inc.) (the amino acid sequences of the light and heavy chain CDR sets of each antibody are described in Table 3, as defined by Kabat). Briefly, human C5a, human C5a des Arg, human full-length C5, or the C5a paralog human C3a and human C4a were passed through the amine group with a stoichiometry of < 1 (biotin):1 (antibody) The clusters are conjugated with biotin and immobilized on streptavidin tips. The loaded tips were then exposed to a solution containing 20 nM anti-C5a IgG antibody. Each antibody binds C5a and desarginated C5a. Anti-C5a IgG antibodies bind neither C3a nor C...

Embodiment 3

[0411] Example 3. Humanization of selected mouse anti-human C5a antibodies

[0412] The variable regions of 2 related mouse anti-human C5a antibodies (5an101ME and 5an185ME) were selected for humanization into full-length IgG antibodies. Humanization of the light and heavy chain variable regions is based on the identification of a single framework region from a human antibody (preferably a germline v-gene) with a high degree of sequence identity to the original murine parent antibody. Methods for identifying suitable candidate framework regions are described in US Patent No. 7,393,648 to Rother and Wu. Frameworks (FW) and complementarity determining regions (CDRs) were defined according to the method described by Kabat, Chothia and IMGT® (International ImmunoGenetics Information System; France). Briefly, database queries were performed independently for light and heavy chain variable regions using various antibody fragments including: complete murine variable regions from F...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Description

[0001] Cross References to Related Applications [0002] This application claims priority and benefit to U.S. Provisional Patent Application Serial No. 61 / 330,260, filed April 30, 2010, and U.S. Provisional Patent Application Serial No. 61 / 471,465, filed April 4, 2011, the disclosures of which are incorporated by reference Incorporated into this article as a whole. technical field [0003] The technical fields are medicine, immunology, molecular biology and protein chemistry. Background technique [0004] The complement system works in conjunction with the rest of the body's immune system to defend against the invasion of cellular and viral pathogens. There are at least 25 complement proteins that exist as complex assemblies of plasma proteins and membrane cofactors. Plasma proteins make up about 10% of vertebrate serum globulins. Complement components carry out their immune defense functions by interacting in a complex but precise series of enzymatic cleavage and membran...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/18
CPCA61K39/395C07K16/18C07K2317/24C07K2317/33C07K2317/34C07K2317/76C07K2317/92A61K2039/505A61K47/60A61P1/16A61P11/00A61P11/06A61P11/16A61P13/02A61P13/12A61P17/02A61P19/02A61P25/00A61P25/04A61P27/02A61P29/00A61P31/04A61P3/06A61P37/00A61P37/02A61P37/06A61P43/00A61P7/00A61P7/02A61P7/04A61P7/06C07K14/472C07K16/461C07K2317/565C07K2317/56C07K16/28C07K2317/51C07K2317/515A61K39/3955A61K45/06C07K2317/21C07K2317/31C07K2317/41C07K2317/52C07K2317/567C07K2317/71C07K2317/94
Inventor R.P.罗瑟D.L.谢里丹P.P.坦伯里尼张裕春
Owner ALEXION PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap